New Jersey is currently home to 1652 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Investigate Efficacy and Safety of Carisbamate As Adjunctive Treatment for Seizures Associated with LGS in Children and Adults
NCT05219617
Recruiting
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Gender:
ALL
Ages:
Between 4 years and 55 years
Trial Updated:
03/20/2025
Locations: Northeast Regional Epilepsy Group, Hackensack, New Jersey
Conditions: Seizures, Lennox Gastaut Syndrome
Register for Updates
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
NCT05067634
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/20/2025
Locations: Northeast Regional Epilepsy Group, Hackensack, New Jersey
Conditions: Partial Epilepsy
Register for Updates
Phase IB/II of CPX-351 for Relapse Prevention in AML
NCT04990102
Recruiting
This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days pending toxicity. The maximum tolerated dose will be used for the phase II expansion portion of the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Acute Myeloid Leukemia (AML) in Remission
Register for Updates
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
NCT04958811
Recruiting
To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Non-squamous Non-small-cell Lung Cancer
Register for Updates
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
NCT04891289
Recruiting
This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated cholangiocarcinoma that cannot be removed with surgery. The researchers want to find out whether the study treatment works better than the standard chemotherapy to delay progression of disease. For the study treatment to be considered better than the standard treatment, the study tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities, Basking Ridge, New Jersey
Conditions: Intrahepatic Cholangiocarcinoma
Register for Updates
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
NCT04865887
Recruiting
This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey
Conditions: Cervical Cancer, Metastatic Cervical Cancer
Register for Updates
MitraClip REPAIR MR Study
NCT04198870
Recruiting
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Cooper University Hospital, Camden, New Jersey
Conditions: Mitral Valve Regurgitation
Register for Updates
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT03572374
Recruiting
The purpose of this study is learn more about how being treated for breast cancer affects patients' employment. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs during and after treatment. The app provides advice for patients to use when having conversations about breast cancer with their employers and their doctors. The app is called TEAMWork (Talking to Employers And Medical staff about Work). In this study, the investigators are... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Memorial Sloan Kettering Basking Ridge (Consent and Follow-up), Basking Ridge, New Jersey
Conditions: Breast Cancer
Register for Updates
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
NCT02468024
Recruiting
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Meridian Health System, Neptune, New Jersey
Conditions: Non-Small Cell Lung Cancer
Register for Updates
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
NCT00588185
Recruiting
This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.
Gender:
MALE
Ages:
All
Trial Updated:
03/20/2025
Locations: Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey
Conditions: Prostate Cancer
Register for Updates
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
NCT06627413
Recruiting
Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/19/2025
Locations: Clinical Site 1, Marlton, New Jersey
Conditions: Schizophrenia or Schizoaffective
Register for Updates